Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: esterina who wrote (545)	4/24/1998 8:59:00 PM
From: JGoren	Read Replies (2) \| Respond to of 1906

Maykin Ho, Biotech Analyst for Goldman, Sachs was on Wall Street Week this Friday, April 24th. She mentioned Amgen has 11 drugs in the pipeline, and she expected the "large" biotechs, such as Amgen to turn their pipelines around. They have suffered some reversals because they are experiencing slowing groth in their existing products (don't we know that as to Amgen). Next areas of excitement for biotechs--cancer and weight loss. Amgen is for her still a long-term favorite, because it trades at a discount to the market and product pipeline is turning around. Another guest, drug analyst for Schroeder's, said that Viagra could be a $10 BILLION drug, 40,000 prescriptions being written per day and there has been no "detailing." She did predict that some of the initial persons prescribed the drug would fall off either because of efficacy or other reasons. Even at 50%, 5 billion sounds like a lot of money.